| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2800235404011 | 23540401 | DALACIN C INJ.SOL 600MG/4ML AMP BTx1AMPx4ML | 02.04 | 2.14 | 2.95 |
| 05/2018 | 2800235406015 | 23540601 | DALACIN C CUT.SOL 1% FLX30ML | 02.01 | 2.12 | 03.04 |
| 05/2018 | 2800235407012 | 23540701 | DALACIN C LOT 1% (W/V) FLx30ML | 02.01 | 2.12 | 03.04 |
| 05/2018 | 2800235408019 | 23540801 | DALACIN C VAG.CR 2% (W/W) TUB x 40G (7 δοσομετρικοί εφαρμοστές) (7 δοσομετρικοί εφαρμοστές) | 4.19 | 4.40 | 06.06 |
| 05/2018 | 2800235409016 | 23540901 | DALACIN C CAPS 300MG/CAP ΒΤx16(BLIST 2x8) | 3.22 | 3.38 | 4.66 |
| 05/2018 | 2800235410012 | 23541001 | DALACIN C GEL.EXT.US 1% (W/W) TUBx30G | 3.10 | 3.27 | 4.68 |
For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.
2.4 hours
Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.